Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

Kitov Pharmaceuticals next catalysts

1) KIT-302's NDA submittal (Q2/2017)

2) NT-219's IND submittal

3) KIT-302's renal study (June 2017)

4) ISA updates

5) KIT-302 License agreements (US, EU and other Countries)

In the meanwhile, it looks like Management is cleaning the structure with the recent 6-K http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11547048&type=HTML&symbol=KTOV&companyName=Kitov+Pharmaceuticals+Holdings+Ltd.&formType=6-K&dateFiled=2017-04-26

Why? Still studying .... and i don't like to speculate.

"On April 25, 2017, the boards of directors of each of the Company and Kitov Pharmaceuticals Ltd., the Company’s wholly owned subsidiary, approved a merger between the two entities, with the Company remaining as the surviving entity. In accordance with the Israeli Companies Law 5759-1999, the proposed merger between the Company and Kitov Pharmaceuticals Ltd. will not require shareholder approvals".

and ....

On April 25, 2017, the Board of Directors of the Company ratified the membership of the committees of the Board of Directors as follows:

a) Audit Committee – Steven Steinberg; Revital Stern-Raff; Arye Weber
b) Compensation Committee – Steven Steinberg; Arye Weber; Ido Agmon
c) Investments Committee – Simcha Rock; Ido Agmon; Arye Weber; Ran Tzror
d) Science & Technology Committee – John Paul Waymack; Gil Ben-Menachem; Ido Agmon

Interesting to note is that Audit Committee's members have been replaced. Interesting because it was the Committee that recommended DMC.

On September 24, 2015 (there is no PR about it) in preparation for the completion of the patient recruitment process for the Company's Phase III trials (hereinafter: the “Trials”) on the KIT-302 drug (hereinafter: the “Drug”), the Company’s Board of Directors, after receiving the recommendation of the Audit Committee, appointed the members of the independent external committee – the Data Monitoring Committee (hereinafter: the “DMC”), which include an expert in the field of statistics as well as a professional in the Company’s areas of activity.

One of them Moran Sherf Blau resigned on September 27, 2016 https://www.streetinsider.com/Management+Changes/Kitov+Pharma+(KTOV)+Director+Blau+Resigns/12074269.html